StockData

Drugs Made In America Acquisition II Corp. (DMII) company profile

DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$10.24+0.00 (+0.05%)

Close on Nov 17, 2026Market cap $140.36MP/E –Yield –

About Drugs Made In America Acquisition II

Blank Checks, SIC 6770

Drugs Made In America Acquisition II Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. The company conducts no commercial operations and generates no revenue, operating solely as a shell company. Its business strategy focuses on acquiring operating entities in the pharmaceutical sector, specifically targeting businesses capable of advancing the domestic manufacturing of active pharmaceutical ingredients and critical finished generic drugs to enhance supply chain resilience.

Because the company has not commenced operations, it has no commercial presence, operational facilities, or physical retail footprint, holding nominal assets consisting almost entirely of cash. The company is incorporated as an exempted entity in the Cayman Islands and maintains its principal executive offices in New York, New York.

Summary of the business section of Drugs Made In America Acquisition II's latest annual report, written by StockData.

Company profile

Company

Legal name
Drugs Made In America Acquisition II Corp.
Founded
2024
Headquarters
New York, NY
Address
420 Lexington Avenue, Suite 1402 10170
Phone
(954) 870-3104
Industry
Blank Checks
Fiscal year ends
December 31
Auditor
MaloneBailey, LLP, Houston, Texas

Stock & identifiers

Ticker
DMII
Other tickers
DMIIR, DMIIU
Exchange
Nasdaq
IPO date
Sep 25, 2025
Shares outstanding
64M, Aug 14, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
2040475
CUSIP
G2851K104
FIGI
BBG01WC234G1
Share class FIGI
BBG01WC235D1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Lynn StockwellCEO and Exe. Chair of Board, Director14,675,000
Glenn C. WormanCFO100,000
Catherine DoDirector100,000
Myron W. ShulganDirector100,000
Sridhar G. PrasadDirector100,000

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Sep 25, 2025
Offer price
$10.00
Securities offered
50,000,000
Gross proceeds
$500.00M
First trading day
Sep 25, 2025
First-day close
$9.99-0.1%
Lock-up ends (est.)
Mar 24, 2026

“Each unit has an offering price of $10.00 and consists of one ordinary share and one right to receive one -tenth (1/10) of an ordinary share upon the consummation of an initial business combination, as described in more detail below, which we refer to throughout this prospectus as the “public rights”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?